NASDAQ:OPGN OpGen (OPGN) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free OPGN Stock Alerts $0.48 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.46▼$0.5050-Day Range$0.26▼$0.5952-Week Range$0.17▼$3.84Volume162,743 shsAverage Volume198,273 shsMarket Capitalization$4.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get OpGen alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About OpGen Stock (NASDAQ:OPGN)OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Read More OPGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPGN Stock News HeadlinesMarch 13, 2024 | americanbankingnews.comOpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.comFebruary 9, 2024 | msn.comOpGen Inc Reports Unregistered Equity Sales UpdateMarch 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.February 9, 2024 | msn.comOpGen Inc. Extends Warrant Exercise Deadline to 2024December 17, 2023 | morningstar.comOpGen Inc OPGNDecember 13, 2023 | bizjournals.comRockville biotech OpGen fights to retain Nasdaq listing as business teetersNovember 15, 2023 | bizjournals.comRockville biotech OpGen shrinks headcount, scales down U.S. operationsNovember 15, 2023 | finanznachrichten.deOpGen, Inc.: OpGen Reports Third Quarter 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… November 14, 2023 | markets.businessinsider.comOpGen Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 12, 2023 | seekingalpha.comOpGen surges after announcing private placementOctober 12, 2023 | finance.yahoo.comOpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross ProceedsOctober 12, 2023 | uk.finance.yahoo.comOpGen, Inc. (OPGN) interactive stock chart – Yahoo FinanceOctober 12, 2023 | marketwatch.comOpGen Shares Take Flight Premarket on Talks for Potential DealOctober 12, 2023 | investorplace.comWhy Is OpGen (OPGN) Stock Up 540% Today?September 29, 2023 | markets.businessinsider.comWhy Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving PremarketAugust 14, 2023 | msn.comHC Wainwright downgrades OpGen amid bankruptcy concernsAugust 13, 2023 | finance.yahoo.comOpGen, Inc. (NASDAQ:OPGN) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | finanznachrichten.deOpGen, Inc.: OpGen Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 11, 2023 | marketwatch.comOpGen Issues Going-Concern Warning, Exploring OptionsAugust 11, 2023 | finance.yahoo.comOpGen Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 9, 2023 | benzinga.comEarnings Outlook For OpGenAugust 7, 2023 | finance.yahoo.comOpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud OfferingAugust 3, 2023 | finance.yahoo.comOpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern TimeAugust 3, 2023 | finance.yahoo.comOpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration AgreementJuly 19, 2023 | finance.yahoo.comOpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FINDJuly 6, 2023 | msn.comBuy 5 Top-Ranked Stocks With Rising P/E in JulySee More Headlines Receive OPGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today3/18/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:OPGN CUSIPN/A CIK1293818 Webwww.opgen.com Phone(240) 813-1260Fax301-869-9684Employees85Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,280,000.00 Net Margins-852.18% Pretax Margin-852.18% Return on Equity-316.30% Return on Assets-89.52% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.18 Sales & Book Value Annual Sales$2.61 million Price / Sales1.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book0.19Miscellaneous Outstanding Shares10,010,000Free Float9,881,000Market Cap$4.85 million OptionableNot Optionable Beta-0.78 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Oliver Schacht Ph.D. (Age 53)CEO, President & Director Comp: $408kMr. Albert Weber (Age 61)CFO & Corporate Secretary Comp: $317.5kMr. Johannes Bacher (Age 55)Chief Operating Officer Comp: $300kMr. Vadim Sapiro (Age 53)Chief Information Officer Comp: $300kMs. Faranak AtrzadehChief Marketing & Scientific Affairs OfficerDr. Theo deVosMD & CEO of Ares GeneticsMore ExecutivesKey CompetitorsInvitaeNYSE:NVTABioNexus Gene LabNASDAQ:BGLCT2 BiosystemsNASDAQ:TTOOPsychemedicsNASDAQ:PMDCentogeneNASDAQ:CNTGView All Competitors OPGN Stock Analysis - Frequently Asked Questions Should I buy or sell OpGen stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OPGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPGN, but not buy additional shares or sell existing shares. View OPGN analyst ratings or view top-rated stocks. How have OPGN shares performed in 2024? OpGen's stock was trading at $0.42 on January 1st, 2024. Since then, OPGN shares have increased by 15.5% and is now trading at $0.4850. View the best growth stocks for 2024 here. When is OpGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our OPGN earnings forecast. How were OpGen's earnings last quarter? OpGen, Inc. (NASDAQ:OPGN) announced its quarterly earnings data on Thursday, August, 10th. The medical research company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.22. The medical research company had revenue of $0.74 million for the quarter, compared to analyst estimates of $0.90 million. OpGen had a negative net margin of 852.18% and a negative trailing twelve-month return on equity of 316.30%. During the same period in the previous year, the firm earned ($2.60) EPS. When did OpGen's stock split? Shares of OpGen reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of OpGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO). When did OpGen IPO? (OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager. How do I buy shares of OpGen? Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPGN) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.